Netramark Holdings expands into phase three programs

Executive Summary

• Netramark Holdings Inc. has been awarded a new contract by a prominent global biopharmaceutical company to provide analytics support for a pivotal Phase 3 clinical trial.
• The engagement is executed under an existing master services agreement and represents a discrete project from a returning sponsor, highlighting continued momentum and trust in the NetraAI platform.
• The project expands Netramark’s role into high-value Phase 3 decision support, utilizing its mathematically augmented AI technology to identify explainable patient subpopulations and analyze treatment versus placebo-response patterns.

Key Details

• Contract Scope: Support for analytics in a pivotal Phase 3 clinical trial.
• Client: A prominent global biopharmaceutical company (specific name not disclosed).
• Agreement Structure: Executed under an existing master services agreement; described as a new, discrete project from a returning sponsor.
• Technology Application: Use of NetraAI to identify and characterize patient subpopulations (responders, non-responders, and placebo-associated participants) based on screening and baseline variables.
• Strategic Value: The work aims to help the sponsor interpret differential response patterns, understand sources of variability, and support evidence-based decision-making for subsequent clinical, regulatory, and commercial planning.
• Market Indication: The win signals growing consideration of NetraAI in late-stage (Phase 3) programs and reinforces the company's position as a partner for improving probability of success in development and regulatory pathways.

Notable Quotes

• "Momentum continues to build for Netramark as more biopharmaceutical companies recognize the value that explainable AI can bring to high-stakes development programs. Being selected for another project under an existing master services agreement -- this time for a pivotal phase 3 trial -- demonstrates the growing trust and confidence that sponsors place in NetraAI." — George Achilleos, Chief Executive Officer